The gap between trailing and forward P/E implies analysts expect trailing net income, depressed by quarterly losses such as the $7.5M net loss in 2026Q3, to normalize materially. Relative to Teva at 34.82x trailing and Perrigo at a negative P/E, AMRX's forward multiple appears reasonable, but this rests on delivery of the consensus earnings path that the recent EPS disclosure gap has made harder to verify. Investors should treat the forward multiple as conditional on operating margin stabilizing rather than as a standalone signal of undervaluation.

Gross margin volatility between 36.0% and 44.3% suggests mix and pricing effects dominate, and the operating-to-net margin gap of roughly 12 points in the latest quarter is largely consistent with interest burden rather than operating weakness. This pattern suggests that the business is operationally profitable at the segment level but that financing costs absorb most of the residual value. The compression warrants monitoring of SG&A growth relative to revenue as a leading indicator.

The reported ROE of 1208.4% reflects a thin equity base after years of accumulated deficits rather than genuine operating excellence, so ROIC is the more reliable measure of capital efficiency here. Returns hovering in the low single digits suggest the debt-funded asset base, including goodwill that rose to $2.3B, is not yet generating economic returns above its financing cost. Sustained improvement would likely require margin recovery alongside disciplined capital deployment.

Interest coverage dipping toward 1.3x leaves limited buffer for any earnings shortfall, and the sharp decline from 2.68x in 2026Q1 suggests rising interest costs or softer operating income are compressing the cushion. The D/EBITDA ratio of 22.08x in the latest quarter is elevated relative to a typical specialty pharma profile, which may constrain refinancing flexibility. Investors should monitor covenant headroom and maturity schedules, as the reported figures alone cannot confirm refinancing access.

A current ratio above 1.8 in the latest quarter appears adequate on the surface, but the quick ratio of 1.24 and the dependence on receivables and inventory, with DSO near 109 days and DIO around 121 days, mean the liquidity position is tied to collection and inventory turnover. Under a severe stress scenario involving slower collections or a write-down of generic inventory, the thin cash base could require external financing. This suggests the liquidity profile is adequate in normal conditions but fragile under stress.

AMRX's ROIC of 2.2% trails Teva's 7.7%, and its net margin is negative compared with Teva's 8.2%, suggesting the operating gap is partly structural given the debt-funded acquisition history rather than purely cyclical. The valuation discount relative to peers appears to reflect the market weighing this leverage against operational growth in biosimilars and specialty products. Whether this gap narrows depends on deleveraging progress rather than revenue growth alone.